Because the transcriptional activity of AR and HIF-1α was attenuated by panobinostat/everolimus combination in vitro, we asked if these events were critical for the superior anti-tumor activity of panobinostat/combination therapy in vivo. This evidence concerns the gene AR and neoplasm.